Cortexyme Appoints June Bray to its Board of Directors
June 13 2022 - 07:00AM
Business Wire
Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage
biopharmaceutical company focused on rare and degenerative
diseases, today announced the appointment of June Bray, a
pharmaceutical industry veteran and global drug development and
regulatory process expert, to the company’s Board of Directors.
“We are very pleased to welcome a seasoned pharmaceutical and
global regulatory expert of June Bray’s caliber to our Board of
Directors,” said David Lamond, chairperson of Cortexyme’s Board of
Directors. “With more than four decades of pharmaceutical industry
experience, we look forward to her valuable contribution and
perspective across multiple therapeutic areas.”
“I am excited to join Cortexyme’s Board of Directors as the
company works to efficiently and effectively advance its current
clinical stage therapeutics, in addition to expanding its
development pipeline in strategic ways,” said June Bray. “I look
forward to supporting the new leadership team as they work to
establish a clear roadmap for driving the company’s clinical stage
and discovery pipeline, and in the evaluation of new business
development opportunities.”
To the Cortexyme Board of Directors, Ms. Bray brings more than
forty years of extensive U.S. and global regulatory experience in
the healthcare industry and a proven track record of successful
regulatory interactions with health authorities which have led to
the approval of 32 NDAs in the U.S. and multiple international
approvals. She most recently served as Senior Vice President,
Global Regulatory Affairs and Medical Writing at Allergan, where
she was responsible for regulatory strategies on development
projects and lifecycle management in all therapeutic areas,
including psychiatry and neurology. During her tenure, she led
numerous NDA approvals, including Namenda XR®, Namzaric®, Vraylar®,
and Ubrelvy®. Previously, Ms. Bray served as Vice President,
Regulatory Affairs at Organon (now Merck), where she led regulatory
activities for development and marketed products, including the NDA
for Saprhis® (asenapine) for the treatment of schizophrenia and
bipolar disorder. Earlier in her career, Ms. Bray held numerous
roles of increasing responsibility over a 25-year period at Berlex
Laboratories, Inc. (now Bayer HealthCare Pharmaceuticals). She
began her pharmaceutical career in sterile manufacturing at
Hoechst-Roussel Pharmaceuticals (now Sanofi-Aventis). Ms. Bray
holds a B.S. in Pharmacy from the University of Rhode Island and an
M.B.A in Pharmaceutical Marketing from Fairleigh Dickinson
University.
About Cortexyme
Cortexyme, Inc. (Nasdaq: CRTX) is a clinical stage
biopharmaceutical company focused on rare and degenerative
diseases. The company’s innovative pipeline includes a precision
bone growth molecule and drug-targeting platform to treat rare
skeletal diseases, bone cancer and injury, in addition to small
molecule therapeutics targeting the infectious pathogen P.
gingivalis’ role in degenerative disease progression, including for
indications such as periodontal disease, oral potentially malignant
disorders, and Alzheimer’s disease, among others. To learn more
about Cortexyme, visit www.cortexyme.com or follow @Cortexyme on
Twitter.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220613005110/en/
Stacy Roughan Cortexyme, Inc. Vice President, Corporate
Communications & Investor Relations ir@cortexyme.com
Quince Therapeutics (NASDAQ:QNCX)
Historical Stock Chart
From Feb 2024 to Mar 2024
Quince Therapeutics (NASDAQ:QNCX)
Historical Stock Chart
From Mar 2023 to Mar 2024